Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma

NCT07898813 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT07898813
Start your 14-day trial Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07898813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 13, 2027
Completion date
August 13, 2029
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma, resectable pancreatic ductal adenocarcinoma